News

Regeneron becomes final major pharmaceutical company to join Trump's MFN initiative

Regeneron will provide Otarmeni — a new gene therapy for an ultra-rare form of genetic hearing loss <a href="https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only">recently approved</a> by the U.S. Food and Drug Administration — for free under a new agreement with the U.S. government.